Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
Commentary|Articles|December 8, 2025
Experts Highlight HR+ and TNBC Trials to Watch Ahead of SABCS 2025
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan
Leading clinicians preview anticipated HR+ and TNBC studies at SABCS 2025.
Advertisement
Advertisement
As anticipation builds for the 2025 San Antonio Breast Cancer Symposium (SABCS), OncLive® asked leading breast cancer specialists to share the hormone receptor (HR)–positive and triple-negative breast cancer (TNBC) presentations they are most eager to follow at this year’s meeting.
Related to this article
The top 5 OncLive TV videos of the week.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Advertisement
Advertisement